ARS PHARMACEUTICALS I

ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024

22 Feb 2024 09:01:00 By Nasdaq GlobeNewswire

ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter

20 Feb 2024 09:01:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting

05 Feb 2024 09:01:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates

09 Nov 2023 16:00:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

09 Nov 2023 11:02:36 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)

06 Oct 2023 09:03:00 By Nasdaq GlobeNewswire

Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology

03 Oct 2023 09:03:40 By Nasdaq GlobeNewswire

FDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional Study

19 Sep 2023 22:49:48 By Nasdaq GlobeNewswire

ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates

10 Aug 2023 16:00:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis

20 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results

15 May 2023 09:00:00 By Nasdaq GlobeNewswire

FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis

11 May 2023 19:01:24 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including Anaphylaxis

09 May 2023 09:10:46 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces FDA Advisory Committee for neffy® for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis

28 Mar 2023 09:39:51 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

23 Mar 2023 16:01:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors

23 Feb 2023 16:01:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis

22 Feb 2023 16:05:01 By Nasdaq GlobeNewswire

ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023

09 Feb 2023 06:30:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

10 Nov 2022 08:00:03 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Closes Merger with Silverback Therapeutics

08 Nov 2022 16:02:00 By Nasdaq GlobeNewswire